Investors purchased shares of Celgene Corp. (NASDAQ:CELG) on weakness during trading hours on Friday. $156.79 million flowed into the stock on the tick-up and $115.61 million flowed out of the stock on the tick-down, for a money net flow of $41.18 million into the stock. Of all equities tracked, Celgene Corp. had the 5th highest net in-flow for the day. Celgene Corp. traded down ($0.74) for the day and closed at $115.53

Several equities analysts recently issued reports on the company. Morgan Stanley restated a “hold” rating and set a $127.00 price objective on shares of Celgene Corp. in a research note on Friday, April 29th. Cowen and Company reaffirmed a “buy” rating and issued a $150.00 target price on shares of Celgene Corp. in a research report on Thursday, July 28th. Bank of America Corp. reaffirmed a “buy” rating and issued a $125.00 target price on shares of Celgene Corp. in a research report on Wednesday, June 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $138.00 target price on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Finally, Vetr lowered Celgene Corp. from a “hold” rating to a “sell” rating and set a $104.37 target price on the stock. in a research report on Monday, July 25th. Four equities research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $137.65.

The firm has a 50 day moving average of $104.45 and a 200-day moving average of $103.46. The company has a market capitalization of $89.55 billion and a PE ratio of 48.83.

Celgene Corp. (NASDAQ:CELG) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.05. The company earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. During the same period in the previous year, the company posted $1.23 EPS. The company’s quarterly revenue was up 20.9% compared to the same quarter last year. Equities research analysts predict that Celgene Corp. will post $5.77 earnings per share for the current year.

In other Celgene Corp. news, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $110.00, for a total value of $11,000,000.00. Following the transaction, the insider now owns 1,022,201 shares of the company’s stock, valued at $112,442,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Robert J. Hugin sold 75,000 shares of the stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $100.16, for a total value of $7,512,000.00. Following the completion of the transaction, the insider now directly owns 1,122,201 shares in the company, valued at approximately $112,399,652.16. The disclosure for this sale can be found here.

Other large investors have made changes to their positions in the company. Jennison Associates LLC increased its stake in shares of Celgene Corp. by 14.1% in the fourth quarter. Jennison Associates LLC now owns 14,106,160 shares of the biopharmaceutical company’s stock valued at $1,689,354,000 after buying an additional 1,741,019 shares during the period. Edgewood Management LLC increased its stake in shares of Celgene Corp. by 5.1% in the fourth quarter. Edgewood Management LLC now owns 7,665,713 shares of the biopharmaceutical company’s stock valued at $918,046,000 after buying an additional 373,288 shares during the period. Morgan Stanley increased its stake in shares of Celgene Corp. by 7.9% in the fourth quarter. Morgan Stanley now owns 3,883,304 shares of the biopharmaceutical company’s stock valued at $465,065,000 after buying an additional 284,929 shares during the period. Bank of Montreal Can increased its stake in shares of Celgene Corp. by 24.1% in the fourth quarter. Bank of Montreal Can now owns 899,073 shares of the biopharmaceutical company’s stock valued at $107,674,000 after buying an additional 174,824 shares during the period. Finally, Eaton Vance Management increased its stake in shares of Celgene Corp. by 5.8% in the fourth quarter. Eaton Vance Management now owns 2,752,996 shares of the biopharmaceutical company’s stock valued at $329,699,000 after buying an additional 150,515 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.